Criteria for the selective use of contrast-enhanced intra-operative ultrasound during surgery for colorectal liver metastases  by Torzilli, Guido et al.
ORIGINAL ARTICLE
Criteria for the selective use of contrast-enhanced intra-operative
ultrasound during surgery for colorectal liver metastases
Guido Torzilli1, Florin Botea1, Matteo Donadon1, Matteo Cimino1, Fabio Procopio1, Vittorio Pedicini2, Dario Poretti2 &
Marco Montorsi3
1Department of Hepatobiliary Surgery, 2Department of Radiology, and 3Department of General Surgery, University of Milan, Humanitas Research Hospital,
Milan, Italy
Abstract
Background: Contrast-enhanced intra-operative ultrasound (CE-IOUS) for colorectal liver metastases
(CLMs) has become a part of clinical practice. Whether it should be selectively or routinely applied
remains unclear. The aim of this study was to define criteria for the use of CE-IOUS.
Methods: One-hundred and twenty-seven patients underwent a hepatectomy for CLMs using IOUS and
CE-IOUS. All patients underwent computed tomography (CT) and/or magnetic resonance imaging (MRI)
within 2 weeks prior to surgery. The reference was histology, and imaging at 6 months after surgery.
Univariate and multivariate analyses were performed. Statistical significance was set at P = 0.05.
Results: Using IOUS an additional 172 lesions in 51 patients were found. CE-IOUS found 14 additional
lesions in 6 patients. Seventy-eight CLMs in 38 patients appeared within 6 months after surgery. The
sensitivity, specificity, positive- and negative-predictive value were 63%, 98%, 100% and 27% for
pre-operative imaging, 87%, 100%, 100% and 52% for IOUS, and 89%, 100%, 100% and 56% for
IOUS+CE-IOUS, respectively. CE-IOUS allowed better tumour margin definition in 23 patients (18%), thus
assisting resection. Analyses indicated that the presence of multiple (P = 0.014), and isoechoic CLMs
(P = 0.049) were independently correlated with new findings at CE-IOUS.
Conclusions: Compared with IOUS, CE-IOUS improved detection and resection guidance. These
additions are significant and demand its use in cases with multiple and isoechoic CLMs.
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Introduction
Contrast-enhanced intra-operative ultrasound (CE-IOUS) was
proposed in 2004 for both colorectal liver metastasis (CLM) and
hepatocellular carcinoma (HCC) detection1 to improve the results
of IOUS. However, the preliminary results remained inconclusive
for CLMs.2–4 Fioole et al. 4 concluded that CE-IOUS did not
appear necessary in CLM surgery because it did not significantly
improve the accuracy of pre-operative CT and IOUS. However, we
demonstrated the accuracy of IOUS and CE-IOUS for CLMs in a
more significant single-centre series using a well-established pre-
operative work-up, histology and adequate minimal follow-up as
reference standards.5 For sure, although CE-IOUS originally
detected new findings in 44–77% of cases,2,3 the rate has decreased
to <20%.4,5 Meanwhile, pre-operative imaging has improved, and
new contrast agents have been introduced.6 Therefore, the place of
CE-IOUS in CLM staging needs to be redefined, and criteria for its
selective adoption rather than its indiscriminate use must be
determined.
Patients and methods
Definitions
Histology of resected specimens and post-operative follow-up
were used as reference standards. Any new CLMs detected within
the first 6 months of follow-up were considered as early post-
operative recurrence and as lesions not detected by pre- and intra-
operative imaging.
On IOUS, a ‘bright’ liver displayed liver–kidney contrast, and
the blurring of both the intrahepatic vessels and diaphragm was
related to diffusely increased liver echogenicity.7
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The presence of at least three lesions was considered multiple
CLMs.
Pre-operative work-up
The pre-operative imaging work-up consisted of an abdominal
US, abdominal magnetic resonance imaging (MRI) and/or com-
puted tomography (CT) and chest spiral CT. CT/MRI was always
performed within 2 weeks of surgery.
A three-phase CT examination was performed with a Philips
Brilliance 64 (Philips, Eindhoven, The Netherlands). CT enhance-
ment was obtained using an iodinated contrast agent (Iomeron
300; Bracco SpA, Milan, Italy).
MRI was performed initially with two different 1.5T magnets
(Philips Achieva, Eindhoven, The Netherlands or Siemens Sym-
phony, Erlangen, Germany) with phase array coils using dynamic
acquisition sequences and liver-specific MR contrast agents
(MultiHance; Bracco SpA and more recently, Primovist: Bayer,
Leverkusen, Germany). In October 2010, diffusion-MRI became
available and was included in all MRI examinations. More
recently, 18-fluordeoxyglucose-positron emission tomography
(FDG-PET) was also adopted for pre-operative imaging.
IOUS and CE-IOUS
IOUS and CE-IOUS were performed using an Aloka Alpha 10
(Aloka Ltd, Tokyo, Japan) equipped with a standard 3–6 MHz
convex probe and an Esaote MyLab Twice (Esaote Ltd, Genoa,
Italy) equipped with a micro T-shaped 3–11 MHz trapezoid scan-
ning transducer. In all patients, an anaesthesiologist injected
2.4 ml of sulfur-hexafluoride microbubbles (SonoVue®; Bracco
SpA) into a peripheral vein. Such use of the contrast agent is
regularly approved in Italy, and specific informed consent was
obtained from all patients.
Inclusion criteria
Patients who underwent surgery for CLM were prospectively
enrolled for systematic exploration with IOUS and CE-IOUS.
Patients who underwent an explorative laparotomy alone after
IOUS and CE-IOUS were excluded from the analysis because
there was no histological tumour confirmation and most were lost
to surgical follow-up.
A minimum 6-month post-operative follow-up was required to
start the analyses.
Patient follow-up
The patients were followed-up in our institution every 3 months
by an expert hepatobiliary team who checked liver function and
serum carcinoembryonic antigen (CEA) and performed a physical
examination, US (2×/year), CT/MRI (2×/year), colonoscopy (1×/
year) and PET (1×/year). At the 6-month follow-up, each patient
underwent CT/MRI unless the 3-month US discovered a new
lesion, in which case CT/MRI was performed earlier.
End-points
The primary end-point was the identification of factors that could
maximize the benefits of CE-IOUS, thus allowing its selective use
during CLM surgery.
The secondary end-points were the overall sensitivity, specific-
ity, positive- and negative-predictive values (PPV and NPV,
respectively) of IOUS and IOUS plus CE-IOUS compared with
pre-operative imaging.
Statistical analysis
Sensitivity, specificity, PPV and NPV were calculated for pre-
operative diagnostic imaging, IOUS, and CE-IOUS based on his-
tological results and evidence of new liver lesions within the first
6 months post-operatively.
For univariate analyses, continuous and categorical variables
were compared with a two-tailed Student’s t-test and the chi-
square test, respectively.
Multivariate analysis was performed using binary logistic
regression.
Analyses were performed to identify factors influencing IOUS
and CE-IOUS detection and rate of missed lesions diagnosed
at follow-up: (i) pre-operative MRI compared with CT;
(ii) pre-operative diagnostic work-up with/without PET;
(iii) multinodular pattern (≥3) at pre-operative imaging; (iv) pre-
operative chemotherapy; (v) ‘bright’ (steatosis) liver at IOUS; (vi)
isoechoic CLM at IOUS; (vii) hyperechoic CLM at IOUS; and
(viii) hypoechoic CLM at IOUS. The P-value was set at 0.05.
Patients
Between October 2007 and March 2011, 136 consecutive patients
underwent a laparotomy after a diagnosis of CLM. Nine patients
(10%) were excluded from the analysis because they had under-
gone an explorative laparotomy alone owing to peritoneal carci-
nomatosis (6 patients) or lymph node metastasis (3 patients). In
total, 127 consecutive patients [77 males and 50 females; mean
age 61 years (median 65; range 29–85)] underwent a liver resec-
tion using IOUS and CE-IOUS. The imaging diagnostic work-up
for all enrolled patients included abdominal US followed by
contrast-enhanced CT in 52 (41%) patients and MRI in 75
(59%); 11 (9%) of the latter 75 patients also underwent diffusion-
weighted imaging. Twelve patients also received percutaneous
contrast-enhanced US (CEUS), and 10 underwent fine-needle
biopsy. Ninety-two (72%) patients also underwent 18-FDG-PET.
The background liver showed diffuse steatosis in 53 (42%)
patients, 4 patients (3%) were cirrhotic, 4 (3%) had chronic hepa-
titis and the remaining 66 (52%) patients had a normal liver; all
patients with liver steatosis had undergone previous systemic
chemotherapy.
The total number of tumours at pre-operative imaging was 447
(median 2; mean 3.5; range 1–30), with a mean diameter of 3.8
(median 3.3; range 1–14) cm for the largest tumour. Sixty-two
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patients (49%) had multiple CLMs at pre-operative imaging.
Table 1 reports the characteristics of the patients’ subject of the
study.
Results
Detection
At IOUS, 617 lesions were detected (mean 4.9; median 3; range
1–48), and 172 were new lesions in 51 patients (40%). IOUS
detected 79 new lesions in 23/52 patients who underwent pre-
operative CT and 93 new lesions in 28 of the 75 patients who
underwent MRI (P = 0.6); of the latter, 11 (12%) were also exam-
ined with diffusion-weighted analyses. IOUS excluded the pre-
operative diagnosis of CLM for two nodules in two patients. IOUS
identified multiple CLMs in 76 patients (60%).
CE-IOUS discovered 14 additional CLMs not observed on
IOUS (mean 2.3, median 2.5, range 1–4) in 6 patients (5%)
(Fig. 1), among whom 1 had no additional sites on IOUS. The two
lesions pre-operatively diagnosed as CLMs but not confirmed by
IOUS were not visualized by CE-IOUS. The diameter of
CE-IOUS-only detected lesions was 0.3–1.1 cm.
Overall, IOUS and CE-IOUS identified 631 CLMs (mean 5,
median 3, range 1–48), and 186 were new lesions not detected by
pre-operative imaging in 52 patients (41%). IOUS and CE-IOUS
detected 83 new lesions in 23 of the 52 patients who underwent
pre-operative CT and 103 new lesions in 29 of the 75 patients who
underwent MRI (P = 0.9) (Fig. 1).
IOUS and CE-IOUS identified 77 patients (61%) with multiple
CLMs. A significantly greater number of new lesions were
detected by IOUS and CE-IOUS in patients with multiple pre-
operative CLMs than in the remaining patient population (4
versus 2.2; P = 0.01)
Among the 23 patients with a ‘bright’ liver, 19 new lesions were
detected by IOUS in 6 patients and by CE-IOUS in 1 patient.
Univariate and multivariate analyses indicated that pre-
operative chemotherapy, and a pre-operative diagnosis of multi-
ple CLMs significantly influenced CLM detection by IOUS
(univariate: P = 0.026 and P = 0.01, respectively; multivariate: P =
0.044 and P = 0.016, respectively) whereas multiple CLMs and
isoechoic lesions significantly influenced CLM detection by
CE-IOUS (univariate: P = 0.023 and P = 0.041, respectively; mul-
tivariate: P = 0.014 and P = 0.049, respectively) (Table 2).
Resection guidance
CE-IOUS allowed better visualization of the primary tumour
margins in 23 of 127 patients (18%), resulting in easier resection
guidance (Fig. 2).
Surgical outcome
All 186 new liver lesions detected by IOUS and CE-IOUS in 52
patients were resected with 445 pre-operatively diagnosed CLMs
and intra-operatively confirmed by IOUS and CE-IOUS. The
lesion distribution was bilobar in 67 patients, limited to the right
hemi-liver in 45 and limited to the left hemi-liver in 15. Five
Table 1 Characteristics of patients in the study
Variable Data
Age (years) 61 (65; 29–85)
Gender
Men 77 (60)
Women 50 (40)
Imaging diagnostic work-up
US 127 (100)
CT 52 (41)
MRI 75 (59)
18-FDG-PET 92 (72)
Liver tumours
At pre-operative imaging 447 (2; 3.5; 1–30)
At IOUS 617 (4.9; 3; 1–48)
At IOUS & CE-IOUS 631 (5; 3; 1–48)
New tumours
At IOUS 172 (3,4; 2; 1–28)
At CE-IOUS 14 (2.3; 2.5; 1–4)
New tumours
At IOUS 51 (40)
At CE-IOUS 6 (5)
Multiple tumours (≥3)
At pre-operative imaging 62 (49)
At IOUS 76 (60)
At IOUS & CE-IOUS 77 (61)
Largest tumour dimension (cm)
At pre-operative imaging 3.8 (3.3; 1–14)
New at IOUS NA
New at CE-IOUS 0.3–1.1
Tumour topography
Left hemi-liver 15 (12)
Right hemi-liver 45 (35)
Bilobar 67 (53)
Macrovascular invasion
Yes 22 (17)
No 105 (83)
Lymph node metastasis
Yes 7 (6)
No 120 (94)
Tumour echogenicity
Isoechoic 59 (45)
Hyperechoic 21 (17)
Hypoechoic 36 (28)
‘Bright’ liver
Yes 23 (18)
No 104 (82)
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patients (4%) underwent a major resection (≥3 segments). In 36
(70%) of the 52 patients with new lesions detected by IOUS and
CE-IOUS, the surgical approach was modified to an additional
limited resection; 3 of the 6 patients with new CLMs detected by
CE-IOUS were included. Histology confirmed all removed
nodules as metastases and detected no additional CLMs.
After a mean follow-up of 19 months (median 14 months;
range 6–48 months), 72 patients (57%) had recurrent disease; in
67 (53%), the liver was involved. Both the mean disease-free sur-
vival and mean hepatic recurrence-free survival were 12 (median
7; range 1–48) months; 16 patients (13%) died during follow-up.
Thirty-eight patients (30%) developed 78 new liver lesions (mean
2; median 1; range 1–10) in another liver segment within 6
months post-operatively; these nodules were all <2 cm in diam-
eter at detection and were considered metastases missed by pre-
(CT/MRI) and intra-operative (IOUS and CE-IOUS) imaging. Of
these, 8 patients (6%) with 21 new CLMs at follow-up had addi-
tional adverse factors at the time of surgery, including lymph node
metastases in 3 (2%) patients, major vascular invasion in 4 (3%)
and both in 1 (0.8%).
Seventeen patients (13%) had new CLMs (all <2 cm in diam-
eter) within 12 months after surgery.
Table 1 Continued
Variable Data
Background liver
Steatosis 53 (42)
Cirrhosis 4 (3)
Chronic hepatitis 4 (3)
Normal 66 (52)
Chemotherapy
Pre-operative 95 (75)
Post-operative 57 (4%)
Both 42 (33)
Data are expressed as mean (median; range) or as a number
(percentage).
FDG-PET; fluordeoxyglucose-positron emission tomography; US, ultra-
sound; CT, computed tomography; MRI, magnetic resonance imaging;
IOUS, intra-operative ultrasound; CE-IOUS, contrast-enhanced IOUS;
NA, not applicable.
127 patients
with ultrasound–guided liver resection for
447 CLM at pre-operative imaging
51 patients
172 new CLM
–1 CLM
46 patients
No new CLM
–1 CLM (confirmed)
1 patient
No new CLM
–1 CLM (confirmed)
5 patients
13 new CLM
4 patients
Additional LR
32 patients
Additional LR No modified surgery
All removed CLM were confirmed
All non resected lesions
were proven to be benign
38 patients
78 new CLM
in 0-6 months
1 patient
1 new CLM
76 patients
No new CLM
–1 CLM
74 patients
No new CLM
IOUS
CEIOUS
SURGERY
HISTOLOGY
FOLLOW-UP
Figure 1 Flow chart showing the additional findings of intra-operative ultrasound (IOUS) and contrast-enhanced (CE)-IOUS and their output
in terms of modified surgery
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Table 2 Uni- and multivariate analysis of factors influencing colorectal liver metastases (CLM) detection at intra-operative ultrasound (IOUS)
and contrast-enhanced (CE)-IOUS
No
Nr (%)
Yes
Nr (%)
χ2
(P-value)
Logistic regression
(P-value)
OR 95% CI
New CLM at IOUS
MRI versus CT
MRI 47 (63) 28 (37) .436 NS
CT 29 (56) 23 (44)
PET
No 26 (74) 9 (26) .061 NS
Yes 50 (54) 42 (46)
Multiple CLM (≥3)
(pre-operative imaging)
No 47 (72) 18 (28) .010 .016 2.5 1.18–5.28
Yes 29 (47) 33 (53)
Pre-operative CHTa
No 23 (77) 7 (23) .026 .044 2.66 1.02–6.94
Yes 51 (54) 44 (46)
Bright liver
No 59 (57) 45 (43) .128 NS
Yes 17 (74) 6 (26)
Isoechoic CLMb
No 37 (65) 20 (35) .421 NS
Yes 34 (58) 25 (42)
Hyperechoic CLMb
No 58 (61) 37 (39) .942 NS
Yes 13 (62) 8 (38)
Hypoechoic CLMb
No 47 (59) 33 (41) .418 NS
Yes 24 (67) 12 (33)
New CLM at CE-IOUS
MRI versus CT
MRI 71 (95) 4 (5) .698 NS
CT 50 (96) 2 (4)
PET
No 33 (94) 2 (6) .746 NS
Yes 88 (96) 4 (4)
Multiple CLM (≥3)
(IOUS)
No 51 (100) 0 (0) .023 .014 1.92 1.13–6.43
Yes 70 (92) 6 (8)
Pre-operative CHTa
No 30 (100) 0 (0) .200 NS
Yes 90 (95) 5 (5)
Bright liver
No 99 (95) 5 (5) .925 NS
Yes 22 (96) 1 (4)
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Of the 2 patients with pre-operatively diagnosed CLMs not
confirmed by IOUS and CE-IOUS and therefore not removed, 1 is
currently alive without recurrence at 27 months after surgery, and
1 had 2 lesions in other liver segments 18 months post-operative
and underwent a re-resection. Neither of the lesions detected
post-operatively were at the site excluded by IOUS and CE-IOUS.
At the univariate and multivariate analyses of factors influenc-
ing early post-operative recurrence, multiple CLMs at pre-
operative imaging and at IOUS/CEIOUS as well as pre- and
post-operative chemotherapy were found to be significant only at
the univariate (P = 0.034, P = 0.019, P = 0.016, respectively).
Table 3 shows the sensitivity, specificity, PPV and NPV of pre-
operative imaging, IOUS and IOUS+CE-IOUS in detecting
Table 2 Continued
No
Nr (%)
Yes
Nr (%)
χ2
(P-value)
Logistic regression
(P-value)
OR 95% CI
Isoechoic CLMb
No 56 (98) 1 (2) .041 .049 2.84 1.72–8.96
Yes 54 (91) 5 (9)
Hyperechoic CLMb
No 89 (94) 6 (6) .237 NS
Yes 21 (100) 0 (0)
Hypoechoic CLMb
No 75 (94) 5 (6) .435 NS
Yes 35 (97) 1 (3)
MRI, magnetic resonance imaging; CT, computed tomography; PET; positron emission tomography; CHT, chemotherapy; OR, odds-ration; CI,
confidence interval.
aData are not available in two patients.
bData are not available in 11 patients.
Figure 2 (a) the margins of the lesion invading the right hepatic vein (RHV) are unclear (?) at intra-operative ultrasound (IOUS); (b) at
contrast-enhanced (CE)-IOUS the lesion (T) becomes clearly visible by its margins and its relation with the right hepatic vein (RHV)
Table 3 Sensitivity, specificity, positive- (PPV) and negative-
predictive values (NPV) of pre-operative imaging, intra-operative
ultrasound (IOUS) and contrast enhanced (CE)-IOUS in patients with
colorectal liver metastases
Preoperative
Imaging
(CT+MRI)
IOUS IOUS+CEIOUS
Sensitivity 63 87 89
Specificity 98 100 100
PPV 100 100 100
NPV 27 52 56
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CLMs. Pre-operative imaging had significantly lower sensitivity
and NPV than IOUS and IOUS+CE-IOUS (P < 0.05). The PPV
was not significant in any comparison. The sensitivity, specificity,
PPV and NPV were not significantly different between IOUS and
IOUS+CE-IOUS.
Adverse reactions and costs
No clinically evident adverse reactions were reported. The addi-
tional cost of CE-IOUS to the surgical procedure, considering the
use of one sample of contrast agent per patient, was 61.36 euro/
patient.
Discussion
Complete surgical clearance of multiple CLMs is justified even in
the presence of vascular infiltration because significant benefits in
long-term survival have been reported.8 Therefore, tumour
staging is crucial, and CE-IOUS was considered to improve IOUS
sensitivity in detecting new CLMs in 21% of patients.2 These
results were partially confirmed by multi- and single-centre
experiences.3,4 However, the conclusions were not consistent. Leen
et al.3 considered CE-IOUS a useful addition to IOUS. Fioole
et al.4 came to the opposite conclusion. These studies were based
on preliminary experiences with small numbers of patients with
CE-IOUS and used different criteria for patient enrolment and
data analysis. Furthermore, the reference standards differed
among the series, and the comparability of results was reduced,
decreasing the impact of comparative analyses.
In 2008, we reported the results of 47 patients operated on for
CLM using a well-established pre-operative diagnostic flow chart,
using histological findings and 6-month post-operative follow-up
as the reference standards. CE-IOUS identified 10 new lesions in 4
patients (9% of those examined, 5% of the CLMs removed and
19% of the new CLMs identified by intra-operative imaging).5
This series provided findings similar to those of Fioole et al.4 but
quite different from those reported initially (Table 4).2,3 The het-
erogeneity of the results and the progressive decrease in the rate of
new findings made it necessary to identify criteria for the more
selective use of CE-IOUS. Therefore, we performed this study,
excluding patients who were part of the previously reported
analysis.2,5 Nevertheless, the 127 consecutive patients enrolled rep-
resent the largest reported series of CE-IOUS for CLMs.
In addition to the larger size of this series, other important
points also differentiate it from most previous reports.
1 All patients underwent pre-operative imaging within 2 weeks
prior to surgery. Although MRI is currently the best tool for
lesion detection, CT remains useful and was when this study
was planned.9–12 Furthermore, the CT and MRI results did not
differ significantly (Table 2).
2 All lesions detected intra-operatively in this series were
removed, and histological confirmation was obtained, whereas
a significant proportion of patients received intra-operative
thermal ablation of the new sites in previous reports.3,4
3 Both histology and 6-month post-operative follow-up were
used as reference standards.
The results of this study were compared with those of previous
studies (Table 4). In the first two reports, new CLMs were identi-
fied by CE-IOUS at rates of 44–77%.2,3 The rate decreased to
17–19% in more recent reports4,5 and to 8% in the present report.
The more recent use of contrast agents [e.g. perfluorobutane
microbubbles (Sonazoid®; GE Healthcare, Oslo, Norway)] for
Kupffer-phase imaging6 has not resulted in significant improve-
ments. This may substantiate the progression of pre-operative
imaging. However, the number of new CLMs detected by IOUS in
this study (24%) was equivalent to previous reports (16–22%).2,4,5
Because a decrease was only observed in the impact of CE-IOUS,
it is likely that it has achieved a steady state of detection capability.
Consequently, the definition of criteria for selective CE-IOUS use
is both justified and mandatory.
We found that patients with multiple CLMs gained a significant
benefit regarding staging completeness with both IOUS and
CE-IOUS (Table 2). However, multiple CLMs are generally asso-
ciated with a higher rate of lesions missed by pre-operative
imaging.8 If this rate loses relevance once the post-operative
follow-up is analysed, it is probable that the careful and routine
use of IOUS and CE-IOUS has limited their impact; indeed,
although significant in univariate analyses, it lacked significance in
a multivariate analysis. This result is important, as the tendency of
modern liver surgery is to approach multiple presentations
Table 4 Patients operated for colorectal liver metastases who presented new lesions at intra-operative ultrasound (IOUS) and constrast
enhanced(CE)-IOUS as reported in the literature
Pts Preop.
CLM
Confirmed
CLM
Pts with NL
IOUS
NL at IOUS Pts with NL
CEIOUS
NL at
CEIOUS
Pts with NL
IOUS+CEIOUS
Total
CLM
Pts with NL
F-UP
Torzilli et al., (7) 24 45 44 5 10 5 8 8 62 0
Leen et al., (8) 57 NA 79 NA 5 13 17 NA 103 NA
Fioole et al., (9) 39 160 85 10 20 2 4 NA 137 NA
Torzilli et al., (10) 47 129 127 20 43 4 10 21 194 10
Present series 127 447 445 51 172 6 14 52 709 38
Pts, patients; CLM, colorectal liver metastases, NL, new lesions; NA, not available.
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conservatively,13 which explains the high rate of operations modi-
fied owing to new findings by IOUS and CE-IOUS (Fig. 1). Effort
must be made to precisely clarify liver involvement; the use of
CE-IOUS in patients at higher risk of missed CLMs meets this
need.
As for multinodularity, isoechoic CLMs were indepen-
dently associated with CLM detection by CE-IOUS. This
ultrasonographic feature of CLMs appears relevant because it may
impact patient prognosis after surgery.14 The relevance of
CE-IOUS to this issue may also have limited its significance regard-
ing the risk of missed lesions.
In contrast to previous reports2,3,5 and the fact that steatosis may
increase the IOUS detectability of CLMs, enhancing their visibil-
ity,14 a ‘bright’ liver was not associated with a significantly higher
rate of detected CLMs (Table 2). Even if not significant, CE-IOUS
allowed the detection of new lesions in five patients with and one
without a ‘bright’ liver (Table 2), suggesting its reduced relevance
in the event that a ‘bright’ liver is observed by IOUS. However,
pre-operative chemotherapy, which should be associated with a
higher rate of steatosis and, consequently, indirectly related to the
presence of a ‘bright’ liver, was significantly linked to higher
detectability by IOUS (Table 2) and, although not significant, at
CE-IOUS (Table 2). It remains difficult to discriminate between
the potentially opposing roles played by the chemotherapeutic
agents, which include (i) shrinking the CLMs and reducing their
visibility15 and (ii) changing the echogenic pattern of both CLMs
and the surrounding parenchyma, thereby increasing lesion
detectability.14 CE-IOUS has shown potential in patients treated
with pre-operative chemotherapy.
As in previous reports,2,5 enhancing the contrast between the
tumour and the surrounding parenchyma ensured better defini-
tion of the tumour margins and the relationship with adjacent
vascular structures (Fig. 2), which aided resection guidance.
In conclusion, this study is the first and largest to report that
CE-IOUS provides significant findings in patients harbouring
multiple and/or isoechoic CLMs on IOUS. The selective use of
CE-IOUS for CLMs should maximize the benefit of this diagnos-
tic tool and reduce the cost of its indiscriminate use.
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